Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Catalent, Inc
Catalent plans to purchase softgel manufacturer Bettera Brands and other portfolio companies from Highlander Partners to expand its consumer health technology platform and respond to consumer demand for soft forms, including gummies, soft chews and lozenges.
CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
- Contract Research, Toxicology Testing-CRO
- OTC, Consumer
- Controlled Release
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Accucaps Industries Limited
- Catalent U.K. Swindon Zydis Limited
- Cook Pharmica LLC
- Juniper Pharmaceuticals
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.